Pharmaceutical - Inflammatory diseases


Current filters:

Inflammatory diseases

Popular Filters

51 to 55 of 55 results

AstraZeneca collaborates with Amgen on five MAbs


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

GSK exercises option for Galapagos drug candidates


Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Germany’s IQWiG finds no added benefit for Pfizer’s Xiapex


In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

EuropeInflammatory diseasesPfizerPharmaceuticalRegulationXiapex

Merck buys in Exelixis’ PI3K-Delta program; returns product to Acumen


California-based Exelixis (Nasdaq: EXEL) says it has granted US drug giant Merck & Co (NYSE: MRK) an…

Acumen PharmaceuticalsExelixisInflammatory diseasesLicensingMerck & CoNeurologicalOncologyPharmaceutical

51 to 55 of 55 results

Back to top